Compare BridgeBio Pharma Inc (BBIO) vs CAVA Group Inc (CAVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs CAVA Group Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while CAVA Group Inc trades at $67.6 (market cap $7.17B). The key difference: BridgeBio Pharma Inc is far larger — about 2.3× CAVA Group Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, CAVA Group Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | CAVA | |
|---|---|---|
Market Cap | $16.61B | $7.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $97.39 |
52-Week Low | $47.29 | $43.59 |
Enterprise Value | $18.16B | $7.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
CAVA trades at $62.42, up 0.31% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong revenue growth to $1.18B in 2025 and has beaten earnings estimates in two of the last three quarters. Recent news highlights anticipation for the Q2 2026 earnings report, with analysts citing strong traffic and expansion as positive catalysts.
Wall Street maintains a bullish outlook with a consensus price target of $91.00, though high valuation multiples and recent net cash outflows pose risks. The stock's investment case hinges on continued execution of its growth strategy amid competitive industry pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About CAVA Group Inc
CAVA is a Mediterranean fast-casual restaurant brand in the US. It offers customizable bowls, salads, and pitas featuring healthy ingredients, while also selling its signature dips and dressings in grocery stores.
Read more on CAVA →
